PT  - JOURNAL ARTICLE
AU  - Inés Yeste-Gómez
AU  - Carmen Guadalupe Rodríguez-González
AU  - Álvaro Giménez-Manzorro
AU  - Arantza Ais-Larisgoitia
AU  - María Sanjurjo-Saez
TI  - Information leaflets for patients with hepatitis C receiving treatment with triple therapy
AID  - 10.1136/ejhpharm-2012-000176
DP  - 2013 Feb 01
TA  - European Journal of Hospital Pharmacy: Science and Practice
PG  - 13--19
VI  - 20
IP  - 1
4099  - http://ejhp.bmj.com/content/20/1/13.short
4100  - http://ejhp.bmj.com/content/20/1/13.full
SO  - Eur J Hosp Pharm2013 Feb 01; 20
AB  - The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.